Characteristics of patients with pulmonary arterial hypertension receiving selexipag in the sphere registry by race and ethnicity

SESSION TITLE: Pulmonary Vascular Disease Posters 3 SESSION TYPE: Original Investigation Posters PRESENTED ON: 10/10/2023 12:00 pm - 12:45 pm PURPOSE: To describe patient and disease state characteristics of patients receiving selexipag by race in a real-world setting, using SPHERE registry data. METHODS: SPHERE (NCT03278002) was a US-based, multicenter, prospective, observational registry that enrolled mostly (91.6%) pulmonary arterial hypertension (PAH) patients (aged ≥18 years) who were prescribed selexipag. Data was collected at routine clinic visits. This descriptive analysis focuses on White, Black/African American and Hispanic patient cohorts. RESULTS: Of 759 patients with PAH, 549 (72.3%) were White, 117 (15.4%) were Black/African American, and 45 (5.9%) were Hispanic; comprising 93.7% of the SPHERE PAH population. A further 26 patients (3.4%) were Asian, and 22 (2.9%) other/unknown. Overall, 50.6% of all patients had idiopathic PAH (51.4% of White, 55.6% of Black/African American, and 37.8% of Hispanic patients) and 27.0% had connective tissue disease (CTD) associated PAH (26.2% of White, 32.5% of Black/African American, and 33.3% of Hispanic patients). Median age at PAH diagnosis and selexipag initiation was 43 and 51 years for Hispanic, 57 and 62 for White, and 56 and 60 for Black/African American patients. All groups were prevalent at selexipag initiation; median time from PAH diagnosis to selexipag initiation was 2.6 years in White, 3.0 years in Black/African American and 4.0 years in Hispanic patients. At selexipag initiation 6-minute walk distance and N-terminal pro B-type natriuretic peptide levels were similar across groups; 53.4% of White, 50.4% of Black/African American and 40.0% of Hispanic patients were WHO Functional Class (FC) III. Baseline risk status per REVEAL 2.0/REVEAL Lite were similar between White and Black/African American patients; however, more Hispanic patients were at low risk. Rates of hypertension, obesity, and coronary heart disease were similar across groups (per medical history). Rates of renal failure (based on serum creatinine) were 11.3%, 21.4% and 4.4%; diabetes 21.7%, 35.0% and 17.8%; CTD 46.6%, 54.7% and 57.8% in White, Black/African American and Hispanic patients, respectively. Around 55% of all patients were on dual and ~10% were on triple therapy at selexipag initiation. Rates of selexipag discontinuation were similar (~34%) across groups at 18 months’ follow-up. CONCLUSIONS: This US-based registry study indicates that in clinical practice, selexipag is prescribed as part of combination therapy for PAH across racial groups despite differences in comorbidities; the Hispanic population is younger and has less severe disease according to WHO FC III data. CLINICAL IMPLICATIONS: While specific descriptions of Black/African American and Hispanic cohorts are valuable and may better reflect the US population underrepresented in large global studies, differences observed highlight the need to look closely at diverse populations. DISCLOSURES: Scientific Medical Advisor relationship with United Therapeutics Please note: 2021 Added 04/17/2023 by Murali Chakinala, value=Honoraria Research study sponsor relationship with Gossamer Please note: 2021-2023 Added 04/17/2023 by Murali Chakinala, value=Grant/Research Support Advisory Committee Member relationship with Merck Please note: 2021-2023 Added 04/17/2023 by Murali Chakinala, value=Consulting fee Advisory Committee Member relationship with Aerovate Please note: 2021-2023 Added 04/17/2023 by Murali Chakinala, value=Consulting fee Advisory Committee Member relationship with V-Wave Please note: 2020-2021 by Murali Chakinala, value=Consulting fee Advisory Committee Member relationship with Express Scripts Please note: 2016 - 2021 by Murali Chakinala, value=Consulting fee Removed 04/17/2023 by Murali Chakinala, source=Web Response Research study sponsor relationship with Janssen Please note: 2016 - 2023 Added 04/17/2023 by Murali Chakinala, value=Grant/Research Support Research study sponsor relationship with Trio Analytics Please note: 2019-2022 by Murali Chakinala, value=Grant/Research Support Research study sponsor relationship with Altavant Please note: 2019-2022 by Murali Chakinala, value=Grant/Research Support Research study sponsor relationship with Acceleron Please note: 2020-2022 by Murali Chakinala, value=Grant/Research Support Research study sponsor relationship with United Therapeutics Please note: 2019 - 2023 Added 04/17/2023 by Murali Chakinala, value=Grant/Research Support Advisory Committee Member relationship with Phase Bio Please note: 2018-2021 by Murali Chakinala, value=Consulting fee Research study sponsor relationship with Phase Bio Please note: 2018-2021 by Murali Chakinala, value=Grant/Research Support Research study sponsor relationship with Liquidia Please note: 2018 - 2021 by Murali Chakinala, value=Grant/Research Support Research study sponsor relationship with Medtronic Please note: 2014 - 2023 Added 04/17/2023 by Murali Chakinala, value=Grant/Research Support Scientific Medical Advisor relationship with Express Scripts Please note: 2020-2021 Added 04/17/2023 by Murali Chakinala, value=Consulting fee Advisory Committee Member relationship with Janssen Please note: 2021 Added 04/17/2023 by Murali Chakinala, value=Honoraria Advisory Committee Member relationship with Altavant Please note: 2021-2023 Added 04/17/2023 by Murali Chakinala, value=Honoraria Scientific Medical Advisor relationship with Bayer Please note: 2021-2023 Added 04/17/2023 by Murali Chakinala, value=Honoraria
更多